Dasatinib Shows Potential to Treat Rare Type of Ovarian Cancer

Dasatinib Shows Potential to Treat Rare Type of Ovarian Cancer
Dasatinib, a drug approved for the treatment of patients with leukemia, could also be used to treat ovarian clear cell carcinoma, a rare form of ovarian cancer. These are the conclusions of a study titled Synthetic Lethal Targeting of ARID1A mutant ovarian clear cell tumours with dasatinib,” published in the journal Molecular Cancer Therapeutics. Ovarian clear cell carcinoma (OCCC) is a distinct histopathologic subtype of epithelial ovarian cancer (EOC) with an incidence of 5 to 25 percent of all ovarian malignancies. “Unfortunately ovarian cancer is often diagnosed when it has grown too far to be completely removed by surgery, which is why we need new ways to tackle it," Prof. Peter Johnson, chief clinician at Cancer Research UK, said in a recent news release. Scientists at London's Institute of Cancer Research discovered that treatment with dasatinib caused ovarian clear cell carcinoma cells in mice to stop growing. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (it
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *